NEW YORK (GenomeWeb) – GeneNews announced today that it has signed a deal to offer three of its cancer diagnostic tests through healthcare services management firm NueHealth.

Under the terms of the three-year arrangement, GeneNews' blood-based ColonSentry, earlyCDT-Lung and Prostate Health Index tests — which are designed for early patient risk stratification in colorectal, lung, and prostate cancers, respectively — will be offered to patients at NueHealth's provider-owned care centers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.